MTOR and hepatocellular carcinoma: Thus, modulation of PI3K/AKT/mTOR pathway through enhanced PTEN, as well as reduced β-catenin/BCL2 and β-catenin/HSP90 expression leads to significantly better survival probability in hepatocellular carcinoma samples.